Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12122090 | 1.00 | ALDH1A1 (0.34) | ALDH1A1TDP1TSHR | |
| SCHEMBL12341104 | 1.00 | ALDH1A1 (0.34) | ALDH1A1TDP1TSHR | |
| SCHEMBL3328176 | 0.77 | — | — | |
| SCHEMBL13337061 | 0.77 | — | — | |
| SCHEMBL12122091 | 0.77 | — | — | |
| SCHEMBL5820203 | 0.71 | — | — | |
| SCHEMBL14670011 | 0.71 | CPA1 (0.36) | ALDH1A1TDP1 | |
| SCHEMBL265274 | 0.71 | — | — | |
| SCHEMBL240166 | 0.69 | — | — | |
| SCHEMBL1566961 | 0.69 | ADH1B (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637696-B2 | Methods for preparing amides and amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130030210-A1 | METHODS FOR PREPARING AMIDES AND AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-31 | — | — | US | disclosed |
| US-8338620-B2 | Methods for the production of C-8 lactam lactone compounds | NOVARTIS AG (CH) | 2012-12-25 | — | — | US | disclosed |
| US-20100130749-A1 | METHODS | NODEN PHARMA DAC (IE) | 2010-05-27 | — | — | US | disclosed |
| CN-101679213-A | New methods | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2142497-A1 | NEW METHODS | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119804-A1 | NEW METHODS | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030210-A1 | METHODS FOR PREPARING AMIDES AND AMINO ACIDS | DNPEP, PTMS, QPCT | ALDH1A1 733/4885TDP1 3083/4885TSHR 3779/4885 |
| US-20100130749-A1 | METHODS | REN, AGTR1, AGTR2 | ALDH1A1 355/4885TDP1 3622/4885TSHR 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.